Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2011 Feb;84(2 Suppl):21-7.
doi: 10.4269/ajtmh.2011.10-0110.

Preclinical vaccine study of Plasmodium vivax circumsporozoite protein derived-synthetic polypeptides formulated in montanide ISA 720 and montanide ISA 51 adjuvants

Myriam Arévalo-Herrera  1 , Omaira Vera, Angélica Castellanos, Nora Céspedes, Liliana Soto, Giampietro Corradin, Sócrates Herrera
Affiliations

Preclinical vaccine study of Plasmodium vivax circumsporozoite protein derived-synthetic polypeptides formulated in montanide ISA 720 and montanide ISA 51 adjuvants

Myriam Arévalo-Herrera et al. Am J Trop Med Hyg. 2011 Feb.

Abstract

Plasmodium vivax circumsporozoite (CS) protein is a leading malaria vaccine candidate previously assessed in animals and humans. Here, combinations of three synthetic polypeptides corresponding to amino (N), central repeat (R), and carboxyl (C) regions of the CS protein formulated in Montanide ISA 720 or Montanide ISA 51 adjuvants were assessed for immunogenicity in rodents and primates. BALB/c mice and Aotus monkeys were divided into test and control groups and were immunized three times with doses of 50 and 100 μg of vaccine or placebo. Antigen-specific antimalarial antibodies were determined by enzyme-linked immunosorbent assay, immunofluorescent antibody test, and IFN-γ responses by enzyme-linked immunosorbent spot (ELIspot). Both vaccine formulations were highly immunogenic in both species. Mice developed better antibody responses against C and R polypeptides, whereas the N polypeptide was more immunogenic in monkeys. Anti-peptide antibodies remained detectable for several months and recognized native proteins on sporozoites. Differences between Montanide ISA 720 and Montanide ISA 51 formulations were not significant.

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
Antibody response of sera from BALB/c mice vaccinated with a mixture of N, R, and C peptides of the Plasmodium vivax circumsporozite (CS) protein formulated in Montanide ISA 720 or Montanide ISA 51, respectively. Each line corresponds to sera of mice immunized with a priming dose of 100 μg of peptide N and C and two boosting doses 150 μg of the three peptide (N + R + C) at 3-week intervals. Higher titers were obtained in groups of mice immunized with C-long synthetic peptides (LSP) than in those immunized with N-LSP, independently on the adjuvant used. Control groups are not shown.
Figure 2.
Figure 2.
Antibody response of sera from Aotus monkeys vaccinated with a mixture of N, R, and C peptides of the Plasmodium vivax circumsporozite (CS) protein formulated in Montanide ISA 720 or Montanide ISA 51, respectively. Groups of six monkeys were primed with 100 μg of each N and C peptide and two boosting doses of 300 μg of the mixed peptide (N + R + C) at 0, 2 and 4 months. Antibody titers were followed 6 and 8 months post immunization. Enzyme-linked immunosorbent assay (ELISA) titers < 1:100 were considered negative.
Figure 3.
Figure 3.
Comparison of in vitro interferon-gamma (IFN-γ) production by Aotus peripheral blood mononuclear cells (PBMCs) measured by ex vivo enzyme-linked immunosorbent spot (ELIspot). Results show the mean values of six monkeys per group immunized with a blend of three PvCS synthetic polypeptides (N, R, and C) formulated in Montanide ISA 720 and Montanide ISA 51, respectively.
See this image and copyright information in PMC

References

    1. Hay SI, Guerra CA, Gething PW, Patil AP, Tatem AJ, Noor AM, Kabaria CW, Manh BH, Elyazar IR, Brooker S, Smith DL, Moyeed RA, Snow RW. A world malaria map: Plasmodium falciparum endemicity in 2007. PLoS Med. 2009;6:e1000048. - PMC - PubMed
    1. Bojang K, Milligan P, Pinder M, Doherty T, Leach A, Ofori-Anyinam O, Lievens M, Kester K, Schaecher K, Ballou WR, Cohen J. Five-year safety and immunogenicity of GlaxoSmithKline's candidate malaria vaccine RTS,S/AS02 following administration to semi-immune adult men living in a malaria-endemic region of The Gambia. Hum Vaccin. 2009;5:242–247. - PMC - PubMed
    1. Brown GV, Moorthy VS, Reed Z, Mendis K, Arevalo-Herrera M, Alonso P. Priorities in research and development of vaccines against Plasmodium vivax malaria. Vaccine. 2009;27:7228–7235. - PubMed
    1. Vekemans J, Leach A, Cohen J. Development of the RTS,S/AS malaria candidate vaccine. Vaccine. 2009;27((Suppl 6)):G67–G71. - PubMed
    1. Bejon P, Lusingu J, Olotu A, Leach A, Lievens M, Vekemans J, Mshamu S, Lang T, Gould J, Dubois MC, Demoitie MA, Stallaert JF, Vansadia P, Carter T, Njuguna P, Awuondo KO, Malabeja A, Abdul O, Gesase S, Mturi N, Drakeley CJ, Savarese B, Villafana T, Ballou WR, Cohen J, Riley EM, Lemnge MM, Marsh K, von Seidlein L. Efficacy of RTS,S/AS01E vaccine against malaria in children 5 to 17 months of age. N Engl J Med. 2008;359:2521–2532. - PMC - PubMed

Publication types

MeSH terms